Wave Life Sciences Ltd.

Company Overview

Business Model: Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing ribonucleic acid ("RNA") medicines, also known as oligonucleotides, to address both rare and common disorders. The Company's proprietary RNA medicines platform, PRISM, integrates multiple modalities, chemistry innovation, and human genetic insights to design and deliver therapeutic candidates. This platform utilizes RNA-targeting modalities such as RNA interference (SpiNA) and RNA editing (AIMers), and intentionally focuses on modulating gene expression at the transcriptome level, avoiding the use of complex delivery vehicles like lipid nanoparticles or viruses by employing clinically proven conjugates (e.g., N-acetylgalactosamine or GalNAc) or free uptake.

Market Position: Wave Life Sciences Ltd. aims to establish a dominant position in the field of oligonucleotides through its PRISM platform, which is described as having the most versatile toolkit of RNA-targeting modalities in the industry. The Company emphasizes its best-in-class chemistry capabilities, including novel chemistry modifications and control over stereochemistry, which are designed to optimize pharmacological properties such as potency, distribution, and durability of effect. The Company maintains strong and broad intellectual property protection for its novel chemistry modifications.

Recent Strategic Developments:

• WVE-007 (Obesity): In December 2025, the Company announced positive interim data from the ongoing Phase 1 single ascending dose (SAD) portion of the INLIGHT clinical trial, demonstrating improved body composition with fat loss similar to GLP-1s at three months, with muscle preservation. Planning is underway to initiate the Phase 2a multidose (MAD) portion of the INLIGHT clinical trial in individuals with higher BMI and comorbidities in the first half of 2026, and new clinical trials evaluating WVE-007 as an incretin add-on and post-incretin maintenance are expected to initiate in 2026.
• WVE-006 (Alpha-1 Antitrypsin Deficiency): In September 2025, the Company announced positive data from the 200 mg single and multidose, and 400 mg single dose cohorts of the RestorAATion-2 study, showing increased M-AAT protein levels and a favorable safety profile. In February 2026, Wave Life Sciences Ltd. announced it had regained full rights to WVE-006 from GlaxoSmithKline Intellectual Property (No. 3) and expects to receive regulatory feedback on a potential accelerated approval pathway by mid-2026.
• WVE-008 (PNPLA3 I148M Liver Disease): The Company expects to file a clinical trial application for WVE-008 in 2026.
• WVE-N531 (Duchenne Muscular Dystrophy): In the third quarter of 2024, the FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation to WVE-N531. The Company plans to file a New Drug Application in 2026 to support accelerated approval of WVE-N531 with monthly dosing, following positive clinical data from the FORWARD-53 trial.
• WVE-003 (Huntington’s Disease): In June 2024, positive clinical data from the SELECT-HD study demonstrated statistically significant, potent, durable, and allele-selective reductions in cerebrospinal fluid mutant huntingtin protein (up to a mean 46%), with preservation of wild-type huntingtin protein, and a statistically significant correlation between mutant huntingtin reduction and slowing of caudate atrophy. In November 2024, the FDA provided supportive initial feedback on a potential accelerated approval pathway and granted Orphan Drug Designation to WVE-003. The Company plans to submit an Investigational New Drug application for a potentially registrational Phase 2/3 study in conjunction with a strategic partner.
• Collaborations: GlaxoSmithKline Intellectual Property (No. 3) selected a third program to advance to a development candidate in September 2025, and a fourth program subsequent to December 31, 2025, triggering program initiation payments. The collaboration with Takeda Pharmaceutical Company Limited terminated in October 2024.

Geographic Footprint: Wave Life Sciences Ltd. is incorporated in Singapore, which also serves as its registered office. Its principal U.S. office, along with research and development facilities, is located in Cambridge, Massachusetts. The Company also operates a multi-use facility in Lexington, Massachusetts, for research, development, and cGMP manufacturing. Additionally, it has laboratory and office space in Japan and wholly-owned subsidiaries in the United Kingdom and Ireland.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no product revenue)
• Operating Margin: -504.4% (2025), -101.9% (2024), -59.9% (2023)
• Net Margin: -478.7% (2025), -89.6% (2024), -50.8% (2023)

Investment in Growth:

• R&D Expenditure: $182.8 million (428.1% of revenue)
• Capital Expenditures: $0.7 million
• Strategic Investments: The Company received a $50.0 million equity investment from Glaxo Group Limited in January 2023 as part of the GlaxoSmithKline Intellectual Property (No. 3) collaboration.

Key Program Research & Development Analysis

WVE-007 (Obesity)

Financial Performance:

• Revenue: Not directly allocated, but R&D expenses for the INHBE program were $15.7 million (+69.1% YoY).
• Operating Margin: Not applicable (R&D program, not a revenue segment).
• Key Growth Drivers: Positive interim Phase 1 SAD data in December 2025 showed a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass at Day 85, with maximum serum Activin E reductions of 78% maintained for at least 85 days, supporting once or twice-yearly dosing. Preclinical studies demonstrated potent and durable INHBE silencing, visceral fat loss with muscle preservation, and comparable weight loss to daily semaglutide injections. WVE-007 curtailed rebound weight gain post-semaglutide and doubled weight loss when added to semaglutide.

Product Portfolio:

• WVE-007 is a GalNAc-conjugated siRNA utilizing the Company's proprietary SpiNA design, targeting inhibin βE (INHBE) mRNA.

Market Dynamics:

• WVE-007 addresses a significant unmet need in obesity by promoting fat loss while preserving muscle mass, a differentiated profile compared to GLP-1 receptor agonists like Saxenda, Wegovy, and Zepbound, which can lead to substantial lean mass loss. The Company faces competition from other investigational GLP-1 receptor agonists, other GLP-1 receptor agonist combinations, and other mechanisms in clinical development. Several companies, including Arrowhead, Rona Therapeutics, Vial, BaseCure Therapeutics, SanegeneBio, and Hengrui, have siRNA programs targeting INHBE in Phase 1 or Phase 1/2 development, while Alnylam and Innovent have preclinical INHBE programs.

WVE-006 (Alpha-1 Antitrypsin Deficiency)

Financial Performance:

• Revenue: Not directly allocated, but R&D expenses for the AATD program were $5.7 million (-51.1% YoY).
• Operating Margin: Not applicable (R&D program, not a revenue segment).
• Key Growth Drivers: Positive data from the RestorAATion-2 study in September 2025 showed total AAT levels of 20.6 µM (including 10.3 µM M-AAT) in one individual during an acute phase response, demonstrating endogenous regulation. In the 200 mg multidose cohort, total AAT reached 11.9 µM (7.2 µM M-AAT), with M-AAT levels reaching 64.4% of total AAT and mutant Z-AAT protein declining by 60.3%. WVE-006 was generally safe and well-tolerated. The Company is accelerating regulatory engagement and expects feedback on a potential accelerated approval pathway by mid-2026. The Company regained full rights to WVE-006 from GlaxoSmithKline Intellectual Property (No. 3) in February 2026.

Product Portfolio:

• WVE-006 is a GalNAc-conjugated RNA editing oligonucleotide (AIMer) designed to correct a single base in the mutant SERPINA1 mRNA, leveraging endogenous ADAR enzymes.

Market Dynamics:

• WVE-006 is a first-in-class RNA editing program in AATD, addressing both lung and liver manifestations of the disease. Current treatments for AATD lung pathology are augmentation therapies (e.g., Prolastin, Aralast NP, Zemaira, Glassia), with no approved therapies for liver pathology. Competitors in preclinical development for RNA editing include Korro Bio and AIRNA. DNA base editing approaches are in Phase 1/2 studies (Beam Therapeutics, YolTech Therapeutics), and prime editing programs are in preclinical or early clinical development (Tessera Therapeutics, CRISPR Therapeutics, Prime Medicine). Other investigational drugs for AATD lung and liver disease are also in clinical development.

WVE-008 (PNPLA3 I148M Liver Disease)

Financial Performance:

• Revenue: Not directly allocated; R&D expenses are included in "Other research and development expenses."
• Operating Margin: Not applicable (R&D program, not a revenue segment).
• Key Growth Drivers: Preclinical studies demonstrated that the PNPLA3 GalNAc-AIMer restores functional PNPLA3 protein and decreases lipid accumulation. The Company expects to file a clinical trial application in 2026.

Product Portfolio:

• WVE-008 is a GalNAc-conjugated RNA editing oligonucleotide (AIMer) designed to restore PNPLA3 function in homozygous PNPLA3 I148M carriers.

Market Dynamics:

• WVE-008 targets PNPLA3 I148M-driven liver diseases, including metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and Alcoholic Steatohepatitis (ASH). There are currently no therapeutic options specifically addressing the root cause of PNPLA3 I148M-driven liver disease. Approved therapies for MASH, such as Rezdiffra and Wegovy, do not directly address the pathology driven by PNPLA3 I148M.

WVE-N531 (Duchenne Muscular Dystrophy)

Financial Performance:

• Revenue: Not directly allocated, but R&D expenses for the DMD program were $19.5 million (+25.3% YoY).
• Operating Margin: Not applicable (R&D program, not a revenue segment).
• Key Growth Drivers: In the third quarter of 2024, the FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation. The FORWARD-53 Phase 1b/2a trial showed WVE-N531 uptake in myogenic stem cells and myofibers, mean skeletal muscle concentrations of approximately 41,000 ng/g, and a 61-day tissue half-life supporting monthly dosing. Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise was observed, along with substantial improvements in muscle health (reduction in fibrosis, inflammation, necrosis, transition to mature muscle). Dystrophin expression averaged 7.8%, with 88% of boys above 5% average dystrophin. WVE-N531 was generally safe and well-tolerated. The Company plans to file a New Drug Application in 2026 for accelerated approval with monthly dosing.

Product Portfolio:

• WVE-N531 is an exon 53 splicing oligonucleotide incorporating PN backbone chemistry, designed to skip exon 53 within the dystrophin gene.

Market Dynamics:

• WVE-N531 targets approximately 8-10% of Duchenne muscular dystrophy cases. The competitive landscape includes four FDA-approved exon skipping therapies (Vyondys 53, Viltepso, Exondys 51, Amondys 45), a microdystrophin gene therapy (Elevidys), and other drug therapies (Emflaza, Agamree, Duvyzat). The Company believes there are no other investigational programs specifically for exon 53 skipping in clinical development.

WVE-003 (Huntington’s Disease)

Financial Performance:

• Revenue: Not directly allocated, but R&D expenses for the HD program were $2.7 million (-77.3% YoY).
• Operating Margin: Not applicable (R&D program, not a revenue segment).
• Key Growth Drivers: The SELECT-HD study demonstrated statistically significant, potent, durable, and allele-selective reductions in cerebrospinal fluid mutant huntingtin protein (up to a mean 46%), with preservation of wild-type huntingtin protein. A statistically significant correlation was observed between mutant huntingtin reduction and slowing of caudate atrophy. WVE-003 was generally safe and well-tolerated. The FDA provided supportive initial feedback on a potential accelerated approval pathway and granted Orphan Drug Designation in November 2024. The Company plans to submit an Investigational New Drug application for a potentially registrational Phase 2/3 study with a strategic partner.

Product Portfolio:

• WVE-003 is a stereopure allele-selective oligonucleotide incorporating PN chemistry, designed to selectively target rs362273, a variant of the single nucleotide polymorphism "mHTT SNP3" associated with the disease-causing mutant huntingtin mRNA transcript.

Market Dynamics:

• WVE-003 targets approximately 40% of the Huntington’s disease population. There are currently no approved treatments that can reverse or slow Huntington’s disease progression, with existing pharmacological therapies only addressing symptoms (e.g., Xenazine, Austedo, Ingrezza). The Company believes it has the most advanced clinical stage program targeting allele-selective mutant huntingtin lowering, facing competition from numerous investigational drugs aimed at slowing progression from companies such as Alnylam, Ionis Pharmaceuticals, and Roche.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Wave Life Sciences Ltd. has never declared or paid cash dividends on its ordinary shares and does not anticipate paying any in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $602.1 million (as of December 31, 2025)
• Total Debt: $17.8 million (Operating lease liabilities as of December 31, 2025)
• Net Cash Position: $584.3 million (as of December 31, 2025)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Operating lease liabilities include $9.6 million due in 2026 and $9.9 million due beyond 2026.

Cash Flow Generation:

• Operating Cash Flow: $(187.5) million (2025)
• Free Cash Flow: $(188.2) million (2025)
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Wave Life Sciences Ltd. employs a hybrid internal and external manufacturing model. The Company operates an internal cGMP manufacturing facility of approximately 90,000 square feet in Lexington, Massachusetts, which commenced production in the fourth quarter of 2017. This facility supports multiple discovery, preclinical, and early clinical-stage programs and provides expertise for manufacturing oligonucleotides across various modalities. The Company also leverages contract manufacturing organizations (CMOs) for drug substance production and additional manufacturing steps such as filling, finishing, labeling, and storage.

Supply Chain Architecture: The Company relies on third parties for the supply of required raw materials. The global shortage of non-human primates has been identified as a risk that could impact preclinical study timelines.

Key Suppliers & Partners:

• Contract Research Organizations (CROs): Engaged to conduct research, preclinical, and clinical activities.
• Contract Manufacturing Organizations (CMOs): Utilized for manufacturing drug product for preclinical studies and clinical trials, as well as for additional manufacturing steps.
• Shin Nippon Biomedical Laboratories Ltd.: A shareholder and contract research organization, providing contract research services.

Facility Network:

• Manufacturing: Lexington, Massachusetts (approx. 90,000 sq ft multi-use facility for cGMP manufacturing, laboratory, and office space).
• Research & Development: Cambridge, Massachusetts (approx. 44,000 sq ft office and laboratory space), Lexington, Massachusetts (additional laboratory space), and laboratory and office space in Japan.
• Distribution: Not explicitly detailed in the filing.

Operational Metrics: Operational metrics such as capacity utilization or specific efficiency measures are not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Wave Life Sciences Ltd. currently has no internal sales, marketing, or distribution capabilities. Future commercialization efforts will require developing these capabilities or entering into collaborations.
• Channel Partners: The Company has a collaboration with GlaxoSmithKline Intellectual Property (No. 3) for research, development, and commercialization of oligonucleotide therapeutics.
• Digital Platforms: Not disclosed.

Customer Portfolio: Enterprise Customers:

• Strategic Partnerships: GlaxoSmithKline Intellectual Property (No. 3) for oligonucleotide therapeutics and Asuragen for companion diagnostics for Huntington’s disease.
• Customer Concentration: Not applicable as a clinical-stage company with no product revenue.

Geographic Revenue Distribution:

• The Company's revenue is derived from collaboration agreements. Specific geographic revenue distribution is not provided, but the Company has operations in the United States, Japan, the United Kingdom, Ireland, and Singapore.

Competitive Intelligence

Market Structure & Dynamics

The biotechnology and pharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The field of RNA medicines, particularly oligonucleotides, is relatively new, leading to increased complexity and uncertainty in regulatory review. Many competitors possess significantly greater financial, technical, and human resources, as well as more extensive experience in drug development, regulatory approvals, manufacturing, marketing, and sales.

Competitive Positioning Matrix

Direct Competitors

Primary Competitors:

• Obesity: Novo Nordisk (Saxenda, Wegovy), Eli Lilly (Zepbound), H2-Pharma (Xenical), Vivus (Qsymia), Currax Pharmaceuticals (Contrave). Other companies with siRNA programs targeting INHBE include Arrowhead, Rona Therapeutics, Vial, BaseCure Therapeutics, SanegeneBio, and Hengrui. Preclinical INHBE programs are pursued by Alnylam and Innovent, while iBio has an antibody program targeting Activin E.
• Alpha-1 Antitrypsin Deficiency: Grifols (Prolastin, Prolastin-C), Takeda (Aralast NP, Glassia), CSL Behring (Zemaira) offer augmentation therapies. Korro Bio and AIRNA have preclinical RNA editing programs. Beam Therapeutics and YolTech Therapeutics are in Phase 1/2 with DNA base editing. Tessera Therapeutics, CRISPR Therapeutics, and Prime Medicine have prime editing programs. Other investigational drugs for AATD lung and liver disease are in clinical development by Krystal Biotech, Mereo BioPharma, Sanofi, Arrowhead Pharmaceuticals, and Takeda.
• Duchenne Muscular Dystrophy: Sarepta Therapeutics (Vyondys 53, Exondys 51, Amondys 45, Elevidys gene therapy), NS Pharma (Viltepso), Catalyst Pharmaceuticals (Agamree), PTC Therapeutics (Emflaza), and Italfarmaco/ITF Therapeutics (Duvyzat). Other companies with broad DMD programs include Capricor Therapeutics, Dystrogen Therapeutics, Edgewise Therapeutics, Regenxbio, Satellos Bioscience, and Solid Biosciences. Preclinical DMD programs are ongoing at Dyne Therapeutics, Precision BioSciences, and Vertex Pharmaceuticals.
• Huntington’s Disease: Teva (Austedo), tetrabenazine (generic), Neurocrine Biosciences (Ingrezza), Haldol (haloperidol), and Tiapridal (tiapride) for symptomatic treatment. Investigational drugs aimed at slowing progression are in clinical development by Alnylam, Annexon Biosciences, Ionis Pharmaceuticals, Roche, Prilenia Therapeutics, PTC Therapeutics / Novartis, Skyhawk Therapeutics, uniQure, and Vico Therapeutics. Discovery or preclinical programs are pursued by Atalanta Therapeutics, Ophidion, Sangamo Therapeutics, Takeda, Sarepta Therapeutics, Voyager Therapeutics, and Novartis.

Emerging Competitive Threats: The Company faces potential threats from new entrants, disruptive technologies such as gene therapy and DNA editing, and alternative solutions that may be more effective, safer, or less expensive.

Competitive Response Strategy: Wave Life Sciences Ltd.'s strategy involves extending its leadership in RNA medicines through continuous innovation of its PRISM platform, rapidly advancing and growing its differentiated portfolio of RNA medicines, and leveraging its manufacturing leadership in oligonucleotides.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company's novel approach to RNA medicines may not lead to marketable products, and the relatively limited experience of regulatory agencies with this class of drugs could increase the complexity and length of the regulatory review process. Market acceptance of new technologies by physicians, payors, and consumers is uncertain. Technology Disruption: Intense competition from major pharmaceutical and biotechnology companies, academic institutions, and other research organizations developing existing therapies, new treatment methods, and new technologies (e.g., gene therapy, DNA editing) for the same diseases. Customer Concentration: Delays or difficulties in patient enrollment for clinical trials, including the identification of specific genetic sequences using companion diagnostic tests, could delay or prevent regulatory approvals.

Operational & Execution Risks

Supply Chain Vulnerabilities: Reliance on third parties for raw materials and manufacturing of product candidates. A limited number of oligonucleotide manufacturers and a global shortage of non-human primates for preclinical studies pose supply chain risks. Supplier Dependency: Dependence on third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) for various aspects of drug discovery, preclinical studies, and clinical trials. Failure of these third parties to perform satisfactorily could harm the business. Geographic Concentration: Operations outside the United States expose the Company to unfamiliar foreign laws, regulatory changes, political or economic instability, currency fluctuations, tariffs, and trade barriers. Capacity Constraints: Limited experience manufacturing drug substance on a commercial scale and potential difficulties in scaling up internal manufacturing capabilities.

Financial & Regulatory Risks

Market & Financial Risks: Wave Life Sciences Ltd. has a history of significant operating losses and will require substantial additional funding. Macroeconomic conditions, including fears concerning the financial services industry, inflation, and volatility in interest rates, could adversely affect the Company's ability to raise capital. Foreign Exchange: Exposure to market risk related to changes in foreign currency exchange rates due to international operations. Credit & Liquidity: The Company's ability to raise additional funds depends on the capital and credit markets, which have experienced extreme volatility and disruption. Regulatory & Compliance Risks: Extensive governmental regulations in the U.S. and foreign jurisdictions (e.g., FDA, EMA, MHRA) govern all aspects of drug development, manufacturing, and commercialization. Ongoing regulatory oversight, potential for delays in clinical trials, the need for companion diagnostic tests, unfavorable pricing regulations, third-party reimbursement practices, and healthcare reform initiatives (e.g., Inflation Reduction Act of 2022) could harm the business. Non-compliance with healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA) could lead to significant penalties. Data Privacy: Security breaches, cybersecurity threats, misuse of AI tools, loss of data, and noncompliance with privacy laws (e.g., GDPR, HIPAA, state privacy laws) could compromise sensitive information, expose the Company to liability, and damage its reputation.

Geopolitical & External Risks

Geopolitical Exposure: Operations in multiple countries (Singapore, U.S., Japan, UK, Ireland) expose the Company to geopolitical conflicts, global economic uncertainty, and changes in international trade policies. Trade Relations: Developments in international trade by the U.S. and foreign governments, including tariffs and trade protection measures, could adversely affect the Company's cost of goods sold and foreign sales. Sanctions & Export Controls: Compliance with trade restrictions, sanctions, and export controls is required for international operations. Natural Disasters & Health Epidemics: Natural disasters or local and global health epidemics could severely disrupt operations, delay preclinical studies and clinical trials, and have adverse effects on the business.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Wave Life Sciences Ltd.'s PRISM platform is central to its R&D, focusing on RNA medicines. Key areas include:

• Stereochemistry: Pioneering novel chemistry modifications to optimize pharmacological properties of oligonucleotides.
• Novel Chemistry Modifications: Introduction of PN backbone chemistry (e.g., phosphoryl guanidine) to increase potency, tissue exposure, and durability across modalities, and base modifications (e.g., N-3-uridine or N3U) to enhance RNA editing efficiency.
• Multiple Modalities: Advancing programs across RNA interference (SpiNA), RNA editing (AIMers), antisense silencing, splicing, and novel bifunctional modalities designed to silence multiple targets or silence one target while simultaneously editing or upregulating another.
• Harnessing Endogenous Enzymes: Leveraging adenosine deaminases acting on RNA (ADAR) enzymes for messenger RNA correction and upregulation. Innovation Pipeline: The Company is actively advancing new targets across multiple disease areas, including emerging siRNA and RNA editing programs targeting both hepatic and extra-hepatic tissues. It is also exploring bifunctional oligonucleotide constructs that combine RNAi and RNA editing or dual RNAi silencing.

Intellectual Property Portfolio: Patent Strategy: Wave Life Sciences Ltd. maintains a strong and broad intellectual property position, with worldwide patent filings protecting stereopure oligonucleotide compositions, specific stereochemical patterns, proprietary synthetic methodologies and reagents, and methods of use. The portfolio includes multiple issued patents in major market jurisdictions (U.S., Europe, Japan) with 20-year expiration dates ranging from 2029 to at least 2045. The Company co-owns filings with the University of Tokyo and Shin Nippon Biomedical Laboratories, Ltd. Licensing Programs: The Company licenses patent rights from third-party owners or licensees to protect certain aspects of its technology and programs. IP Litigation: The Company faces the risk of third-party claims alleging infringement of patents or other proprietary rights, or challenges to its own patent rights, which could be costly and time-consuming.

Technology Partnerships:

• Strategic Alliances: Collaboration with GlaxoSmithKline Intellectual Property (No. 3) for discovery and development of oligonucleotide therapeutics, leveraging GlaxoSmithKline Intellectual Property (No. 3)'s genetic insights.
• Research Collaborations: Collaboration with Asuragen for the development and commercialization of companion diagnostics for its allele-selective therapeutic programs targeting Huntington’s disease.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company is highly dependent on its senior management and scientific, clinical, and medical staff and advisors. The loss of key personnel could materially harm the business. The Company expects to continue recruiting and hiring qualified personnel as it expands operations.

Board Composition: The Board of Directors is actively involved in overseeing human capital strategy, including succession planning and compensation. Specific details on board independence, expertise areas, or committee structure are not provided in this filing.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of December 31, 2025, Wave Life Sciences Ltd. employed 317 full-time employees.
• Geographic Distribution: Not explicitly detailed, but employees are located across the Company's global operations.
• Skill Mix: The Company aims to build and retain an exceptionally skilled, highly innovative team, with a significant number of management and employees having prior experience in pharmaceutical, biotechnology, or medical product companies.

Talent Management: Acquisition & Retention: The Company's strategy focuses on being an employer of choice, maintaining a culture that emphasizes respect, inclusion, collaboration, and continuous development. It offers a differentiated total rewards package, including base salary, cash bonuses, benefits, and equity compensation for all employees, to attract and retain top talent. Development Programs: Wave Life Sciences Ltd. invests in regular leadership and management development programming to strengthen coaching and communication capabilities. Culture & Engagement: The Company conducts regular employee surveys to inform workforce engagement initiatives and was recognized by the Boston Business Journal as one of the 2024 "Best Places to Work."

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed.
• Development Programs: Training, leadership development, and career advancement programs are in place.
• Culture & Engagement: The Company fosters a culture of respect, inclusion, and collaboration, with a focus on employee satisfaction and workplace flexibility.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: The Company's environmental, health, and safety ("EH&S") policy and programs are based on compliance with EH&S laws and regulations. Supply Chain Sustainability: Not explicitly detailed.

Social Impact Initiatives: Community Investment: The Company engages in community activities to understand the experiences of people impacted by diseases, supports these communities, and collaborates with patient communities and advocacy organizations. Employee volunteering is also a component of its community engagement.

Business Cyclicality & Seasonality

Demand Patterns: Not explicitly discussed for current operations as a clinical-stage company. Seasonal Trends: Not disclosed. Economic Sensitivity: Not disclosed. Industry Cycles: Not disclosed. Planning & Forecasting: Not disclosed.

Regulatory Environment & Compliance

Regulatory Framework: Wave Life Sciences Ltd. is subject to extensive governmental regulations in the United States (by the FDA) and foreign jurisdictions, covering all aspects of drug development, including research, testing, manufacturing, quality, safety, efficacy, approval, labeling, promotion, pricing, marketing, and distribution. Industry-Specific Regulations:

• FDA Approval Process: This includes preclinical testing (GLP), Investigational New Drug (IND) submissions, Institutional Review Board (IRB) approvals, human clinical trials (GCP, Phases 1-4), New Drug Application (NDA) submissions, FDA review, pre-approval inspections (cGMP, GCP), advisory committee reviews, user fees, Risk Evaluation and Mitigation Strategies (REMS), and Pediatric Research Equity Act (PREA) requirements. The Company may also seek expedited development and review pathways such as Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval.
• International Compliance: The Company must obtain approvals from regulatory authorities in non-U.S. countries, such as Clinical Trial Applications (CTAs) in Europe, which are now subject to a harmonized assessment process via the Clinical Trials Information System (CTIS). Marketing Authorization Applications (MAAs) in the European Union follow centralized, decentralized, or mutual recognition procedures. The In Vitro Diagnostic Device Regulation (IVDR) (EU) 2017/746 applies to companion diagnostics. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulation, with changes introduced by the Windsor Framework effective January 1, 2025.
• Other Healthcare Laws: Compliance with U.S. federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act) and analogous foreign laws is required. Trade & Export Controls: The Company's international operations are subject to trade protection measures, import or export licensing requirements, trade embargoes, and sanctions. Legal Proceedings: Wave Life Sciences Ltd. is not currently a party to any material legal proceedings. Singapore Patents Act Section 34: The Company has had instances of undertaking patent filings outside of Singapore without prior written authorization from the Singapore Registrar of Patents, as required by Section 34 of the Singapore Patents Act. The Company has notified the Registrar and implemented measures to address these requirements. Approximately 140 patent applications have been submitted to the Intellectual Property Office of Singapore (IPOS) for review regarding compliance with Section 34.

Tax Strategy & Considerations

Tax Profile: Wave Life Sciences Ltd. is a Singapore multi-national company subject to income and other taxes in the United States, Japan, Singapore, and the United Kingdom. As of December 31, 2025, the Company has recorded a full valuation allowance against its net operating loss carryforwards and federal and state tax credits in all jurisdictions due to uncertainty regarding future taxable income. Effective Tax Rate: The Company's effective income tax rate was 0.0% for the years ended December 31, 2025, and 2024, and 1.2% for the year ended December 31, 2023. Geographic Tax Planning: The Company has intercompany service arrangements with transfer pricing assumptions, which are monitored for compliance with applicable transfer pricing laws. Tax Reform Impact: The One Big Beautiful Bill Act of 2025 (OBBBA) reinstated immediate expensing of certain U.S.-incurred research and experimental expenses for tax years beginning after December 31, 2024, while non-U.S. R&D expenses remain subject to 15-year amortization. The U.K. Finance Act 2024 combined R&D tax credit regimes, reducing the credit rate to 20% (net 16.2%) and tightening rules on eligible overseas subcontracted R&D work. The Inflation Reduction Act of 2022 (IRA) includes provisions that may impact drug prices in the Medicare program, such as rebates for price increases exceeding inflation and drug price negotiation by CMS.

Insurance & Risk Transfer

Risk Management Framework: The Company's cybersecurity practices, policies, and standards are based on recognized frameworks (NIST, CIS, COBIT) and integrated into its overall risk management systems. The Board of Directors oversees risk management, with the Audit Committee specifically overseeing information technology, data privacy, and cybersecurity risks. Insurance Coverage: Wave Life Sciences Ltd. maintains workers’ compensation insurance. However, it does not maintain insurance for environmental liability or toxic tort claims. The Company notes that clinical trial and product liability insurance is becoming increasingly expensive. Risk Transfer Mechanisms: Not explicitly detailed in the filing.